Autologous Endothelial Cells (ECs) have become increasingly vital for providing vascular networks to regenerated organs and a source for autologous cell therapy of ischemic disorders. Additionally, new techniques are arising that make in utero transplantation of functional cells a viable alternative to treating congenital disorders. Here we explore the promise of direct reprogramming in which a mature cell type can be reprogrammed into a distinct mature cell type without passing through the pluripotent phase. The lab has established an efficient method of isolating autologous placenta-derived mesenchymal stem cells (PMSCs) from placental tissue left over from chorionic villus sampling (CVS). We developed proof of principle for using transcription factors and small molecules to directly reprogram early gestational PMSCs into ECs. The E26 transformation specific (ETS) transcription factor ETV2 was shown to increase expression of vital endothelial cell markers and EC morphology when virally transduced in combination with the presence of the vascular endothelial growth factor (VEGF). We also explored methods of indirectly activating ETV2 expression through the use of the small molecule cAMP. The results suggested that these treatments are feasible options for further exploration and optimization of direct reprogramming techniques for the development of functional autologous endothelial cells.